Cargando…

Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study

PURPOSE: To assess the association between BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine and the risk of active noninfectious uveitis (NIU). DESIGN: Retrospective, population-based study. PARTICIPANTS: Two million six hundred two thousand five hundred fifty-seven people who received the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomkins-Netzer, Oren, Sar, Shaul, Barnett-Griness, Ofra, Friedman, Binyamin, Shyriaieva, Hana, Saliba, Walid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American Academy of Ophthalmology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132378/ https://www.ncbi.nlm.nih.gov/pubmed/35643168 http://dx.doi.org/10.1016/j.ophtha.2022.05.015

Ejemplares similares

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Shibli, Rana, et al.
Publicado: (2021)

Red cell distribution width and all-cause mortality in patients with atrial fibrillation: A cohort study
por: Saliba, Walid, et al.
Publicado: (2017)

Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
por: Duran, M.
Publicado: (2022)

Lymphopenia and mortality among patients undergoing coronary angiography: Long-term follow-up study
por: Zafrir, Barak, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Biologics for the treatment of noninfectious uveitis
por: Lin, Chang-Ping
Publicado: (2018)

Intraocular therapy in noninfectious uveitis
por: Modugno, Rocco Luigi, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
por: Hammerman, Ariel, et al.
Publicado: (2022)

Voclosporin as a Treatment for Noninfectious Uveitis
por: Schultz, Clyde
Publicado: (2013)

Targeting interleukin-6 for noninfectious uveitis
por: Lin, Phoebe
Publicado: (2015)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Long‐Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention
por: Zafrir, Barak, et al.
Publicado: (2019)

Clinical Outcomes of Cyclosporine Treatment for Noninfectious Uveitis
por: Lee, Sun Ho, et al.
Publicado: (2012)

Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
por: Hunter, Rebecca S, et al.
Publicado: (2011)

New pharmacotherapy options for noninfectious posterior uveitis
por: Pleyer, Uwe, et al.
Publicado: (2021)

Noninfectious Uveitis in Rheumatology: Patterns, Treatment, and Outcomes
por: Younus, Raheel, et al.
Publicado: (2023)

Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine
por: Saleh, Ola Ali, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
por: Myung, Jane S, et al.
Publicado: (2010)

Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis
por: Palla, Swetha, et al.
Publicado: (2015)

Noninfectious uveitis: strategies to optimize treatment compliance and adherence
por: Dolz-Marco, Rosa, et al.
Publicado: (2015)

Management of noninfectious posterior uveitis with intravitreal drug therapy
por: Tan, Hui Yi, et al.
Publicado: (2016)

The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
por: Park, Sung Eun, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine
por: Amir, Ofra, et al.
Publicado: (2022)

Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis
por: Roesel, Martin, et al.
Publicado: (2011)

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis
por: Pasadhika, Sirichai, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e1tfqgdtg8ge7v04ug6sjnvfj5